The citation metrics supplied for this review β h-index 1, one total citation, and two papers (an Italian-language study of in vitro antibiotic sensitivity of mastitis agents in the Triveneto region, and a case report of medullary thyroid carcinoma with divergent lymph-node metastasis differentiation) β correspond to a small OpenAlex profile with 2 works, 1 citation, and no listed institution ( and ). Neither of these works appears in the supplied paper-level citation record, and neither matches the top OpenAlex profile (A5015053965: 53 works, 702 citations, h-index 13, hematology/oncology focus with a 193-citation nationwide survey of carbapenem-resistant Klebsiella in transplant recipients and a 113-citation HCV/lymphoma study). This strongly suggests at least two β probably three β distinct scientists share the name, and the requested metrics belong to the junior/minor profile.
Judging the profile the metrics actually describe: one citation across two papers (one veterinary-microbiology surveillance study, one single-case oncology report) is a minimal scientific footprint with no established independent research program, no citation network, and no listed affiliation to verify output. Single-author case reports and regional surveillance studies can be legitimate, useful contributions, but they do not by themselves demonstrate methodological depth, reproducibility, or conceptual novelty. Confidence: moderate β limited by the impossibility of confirming which entity is the intended author and by sparse metadata (no affiliations, no funding or COI details available for the two listed papers).
OpenAlex author disambiguation is known to be error-prone, so the supplied h-index of 1 could undercount if works are split across entities; conversely, attributing the h-index-13 profile's output to this author would be a serious over-credit. Resolution via ORCID (none listed for the small profile), full-text author-affiliation checks, and coauthor-network overlap would be required to finalize any score. If the intended author is the hematology profile, this entire assessment would need rewriting.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.